Related topics

ChemoCentryx: 3Q Earnings Snapshot

November 8, 2018

MOUNTAIN VIEW, Calif. (AP) _ ChemoCentryx Inc. (CCXI) on Thursday reported a loss of $10.9 million in its third quarter.

The Mountain View, California-based company said it had a loss of 22 cents per share.

The results surpassed Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research was for a loss of 25 cents per share.

The biopharmaceutical company posted revenue of $9 million in the period, which fell short of Street forecasts. Three analysts surveyed by Zacks expected $11.6 million.

ChemoCentryx shares have increased 97 percent since the beginning of the year. In the final minutes of trading on Thursday, shares hit $11.70, a climb of 51 percent in the last 12 months.


This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on CCXI at https://www.zacks.com/ap/CCXI

Update hourly